Browse recruiting and upcoming clinical trials for polymyositis.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults aged 18–60 with refractory idiopathic inflammatory myopathy (IIM), including dermatomyositis, immune‑mediated necrotizing myopathy, polymyositis, or antisynthetase syndrome.
What is being studied AITests safety and tolerability of a single ICG318 CAR‑T infusion after lymphodepletion.
Who can join AIPeople with refractory juvenile dermatomyositis, polyarticular juvenile idiopathic arthritis, systemic sclerosis, or primary Sjögren's syndrome.
What is being studied AITests BCMA/CD70-targeted CAR-T cell therapy for refractory pediatric rheumatic diseases.
Who can join AIAdults with rheumatic inflammatory diseases (e.g., RA, psoriatic arthritis, AS, SLE, JIA and related conditions) scheduled for elective total shoulder arthroplasty.
What is being studied AICompares shorter versus standard preoperative immunosuppressant holds and post-op restart timing on surgical and rheumatic outcomes.
Who can join AIAdults 18–65 with severe, treatment-refractory B cell–mediated systemic autoimmune diseases (SLE, systemic sclerosis, dermatomyositis/polymyositis, or ANCA-associated vasculitis).
What is being studied AITests a single-dose anti-CD19 CAR T-cell infusion for safety and preliminary efficacy.
Who can join AIPeople age 6–75 with active idiopathic inflammatory myopathy, including dermatomyositis, anti‑synthetase syndrome, immune‑mediated necrotizing myopathy, or juvenile myositis.
What is being studied AITests safety and efficacy of CABA-201 (autologous CD19 CAR-T) in active myositis.
Who can join AIFemale adolescents (12–18 years) with a confirmed chronic pediatric rheumatic disease, such as JIA, lupus, dermatomyositis, or vasculitis.
What is being studied AITests a self-guided web sleep program (BNBD-Youth) and tracks sleep and pain outcomes in teens.
Who can join AIChildren aged 6 to 18 with juvenile arthritis, juvenile idiopathic arthritis, juvenile dermatomyositis, or systemic lupus who are scheduled for injections or blood sampling.
What is being studied AITests whether hypnotherapy reduces anxiety and pain during needle procedures in children.
Who can join AIPeople with one of several autoimmune diseases (age eligibility varies by condition: most groups are 18–50, but dermatomyositis/juvenile dermatomyositis may include patients as young as 5): RA, SLE, systemic sclerosis, ankylosing spondylitis, juvenile idiopathic arthritis, or polymyositis/dermatomyositis.
What is being studied AICompares one infusion of allogeneic MSCs with saline placebo for several autoimmune diseases.
Who can join AIAdults (≥18) with active idiopathic inflammatory myopathy (dermatomyositis, polymyositis, IMNM, antisynthetase syndrome) who completed ARGX-113-2007.
What is being studied AITests long-term safety, tolerability, and clinical effects of subcutaneous efgartigimod in adults with myositis.
Who can join AIAdults with interstitial lung disease associated with rheumatic or connective tissue diseases (eg, systemic sclerosis, rheumatoid arthritis, dermatomyositis, Sjogren's).
What is being studied AITests home-based remote lung-function and symptom monitoring versus scheduled hospital visits.
Who can join AIAdults with systemic sclerosis, other connective tissue diseases (including SLE, dermatomyositis, ANCA-associated vasculitis) and healthy adult volunteers.
What is being studied AIMeasures neutrophil extracellular traps (NETs) quantity and composition in blood from patients and healthy volunteers.
Who can join AIAdults with rheumatic autoimmune diseases (for example rheumatoid arthritis, lupus, scleroderma, ankylosing spondylitis) and healthy adult volunteers.
What is being studied AICollects clinical data and biospecimens (blood, saliva, urine, stool, tissue) for research.
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.
Who can join AIAdults 18–70 with relapsed or refractory Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus, or Systemic Sclerosis meeting protocol criteria.
What is being studied AITests anti-CD19/BCMA universal CAR-T cells (KN3601) as a treatment for refractory autoimmune diseases.
Who can join AIPeople 18+ with dermatomyositis or connective-tissue–related interstitial lung disease who have anti‑MDA5 antibodies and rapidly progressive ILD.
What is being studied AITests intravenous emapalumab treatment for anti‑MDA5 antibody positive rapidly progressive interstitial lung disease.
Who can join AIPeople aged 5 and older with refractory juvenile dermatomyositis or SRP/HMGCR‑positive immune‑mediated necrotizing myopathy meeting RJDM criteria.
What is being studied AITests a single infusion of CD19 universal CAR‑T cells for refractory juvenile dermatomyositis.
Who can join AIPeople with antiphospholipid syndrome, bullous pemphigoid, Behçet's syndrome, dermatomyositis, immune‑mediated necrotizing myopathy, or immune thrombocytopenia.
What is being studied AITests multiple doses of RAY121 (classical complement pathway inhibitor) for safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy.
Who can join AIAdults with autoimmune diseases (for example rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis) who also have advanced or metastatic cancer.
What is being studied AITests safety and activity of nivolumab alone and with other cancer treatments; collects biospecimens.
Who can join AIAdults (≥18) with Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis, Multiple Sclerosis, Dermatomyositis, or Systemic Sclerosis who previously received KYV-101.
What is being studied AICollects long-term safety and persistence data after KYV-101 CAR T-cell treatment.
Who can join AIAdults with various chronic inflammatory skin diseases (for example atopic dermatitis, psoriasis, hidradenitis suppurativa, cutaneous lupus), adults with active leprosy, or healthy skin‑surgery controls.
What is being studied AICollects blood, skin and other samples to find biomarkers linked to treatment response over time.
Who can join AIPeople aged 6–99 with autoimmune, dysimmune, or auto‑inflammatory skin diseases (for example bullous diseases, cutaneous lupus, psoriasis).
What is being studied AICollects biological samples and clinical data to identify biomarkers and study disease mechanisms.